Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Crenezumab dose level 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Double-blind treatment window: Crenezumab dose level 1 | EXPERIMENTAL | Participants will recieve crenezumab dose level 1 once every 4 weeks. |
| Double-blind treatment window: Crenezumab dose level 2 | EXPERIMENTAL | Participants will receive crenezumab dose level 2 once every 4 weeks. |
| Double-blind treatment window: Crenezumab dose level 3 | EXPERIMENTAL | Participants will receive crenezumab dose level 3 once every 4 weeks. |
| Double-blind treatment window: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to crenezumab once every 4 weeks. |
| Optional OLE window: Crenezumab | EXPERIMENTAL | Participants will receive crenezumab dose levels 1 2, or 3 once in every 4 weeks. |
| Name | Type | Description |
|---|---|---|
| Crenezumab dose level 1 | DRUG | Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window. |
| Crenezumab dose level 2 | DRUG | Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window. |
| Crenezumb dose level 3 | DRUG | Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window. |
| Placebo | DRUG | Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window. |
Inclusion Criteria: * Body weight greater than or equal (\>/=) 45 kilograms (kg) and less than or equal (\</=) 120 kg * Ages 50-90 years, inclusive * Availability of a person ("caregiver") who, in the investigator's judgment, has frequent and sufficient contact with the participant and is able to p...
Top 20 of 24 competitors
Crenezumab dose level 1 is an investigational small molecule being studied for the treatment of Alzheimer Disease. It is currently in Phase 1 clinical development. The drug is being evaluated in patients with mild to moderate Alzheimer Disease, as part of a placebo-controlled, double-blind, randomized trial.
Crenezumab dose level 1 targets amyloid beta, a protein that forms plaques in the brains of people with Alzheimer Disease. By binding to amyloid beta, the drug aims to reduce plaque accumulation and potentially slow disease progression. This mechanism is being investigated in clinical trials.
Crenezumab dose level 1 is being developed by Roche Holding AG, a multinational healthcare company. Roche is conducting clinical trials to evaluate the safety and efficacy of this drug for Alzheimer Disease. The company's stock is traded under the ticker RHHBY.
Crenezumab dose level 1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a completed Phase 1 trial involving 77 participants with mild to moderate Alzheimer Disease.
Crenezumab dose level 1 is associated with clinical trial NCT02353598, titled 'A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease'. This Phase 1 trial was conducted in the United States and has been completed. The study enrolled 77 participants and was randomized, double-blind, and placebo-controlled.
Crenezumab dose level 1 is a specific dose level of the drug crenezumab. Crenezumab is being developed by Roche for Alzheimer Disease. The dose level 1 refers to a particular dosage being tested in clinical trials, while crenezumab is the broader drug name.